Navigation Links
Cord Blood America Says Balance Sheet Significantly Strengthened in 2009
Date:8/17/2009

SANTA MONICA, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that its 10Q filing with the U.S. Securities & Exchange Commission for the second quarter of 2009 shows a significantly improved balance sheet.

At June 30, 2009, Cord Blood America's working capital had increased by almost $4 million compared to year-end 2008. This is a 90 percent improvement in only six months.

The Company also had a balance of $324,549 in cash, an important increase as Cord Blood America moves forward with organic growth and possible acquisitions.

Further the 10Q has a schedule detailing the repayment of $5 million in debt in the first half of the year, one of the pillars needed for the Company to succeed.

"While revenues were down, due to very difficult economic conditions, and a significant de-emphasis on our advertising business, we are confident we have built the strong foundation necessary for the growth our shareholders want," said Matthew Schissler, founder and CEO.

"In addition, we anticipated being cash flow positive this year. However one time charges in Q2 including the cost of capital for the $7.5M raised, and significant testing and auditing of our SOP's, coupled with the excellent opportunity to build one of the largest stem cell storage facilities in the country, delayed this in the short term. There were significant sunk costs in Q2 that couldn't be avoided. All measures were taken to strengthen CBAI for the long term."

Mr. Schissler concluded: "Once the s
'/>"/>

SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Heroes of Chemistry for saving teeth, clean water, new high blood pressure drug
2. Bayer Statement on U.S. Food and Drug Administration Advice for Patients: Serious Errors with Certain Blood Glucose Monitoring Test Strips
3. BD and PEPFAR Collaboration Will Improve Blood-Drawing Practices in Hospitals and Clinics in Sub-Saharan Africa
4. MRI Simulation of Blood Flow Helps Plan Childs Heart Surgery
5. Cold, Flu or Pneumonia? Answer May Lie in Blood Test
6. U.S. Navy Awards Entegrion Contracts for $4 Million for the Development of Critical Blood Products
7. Memorial Blood Centers Joins Extreme Makeover: Home Edition As Designated Charity
8. Blood transfusion study: Less is more
9. Gut Hormone Could be Key to Blood Sugar
10. GenVaults GenSolve(TM) Reagents Enable State-of-the-Art Genomic Analysis of Dried Blood Spots
11. Silenced genes as a warning sign of blood cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ctoryPharma,Inc.("Victory")announcedtodaythelaunch...y,sNAPRELANfranchise. ,, NAPRELANDoseCardisdesi...ainandinflammationassociatedwithprimarydysmenorrhe...patientssufferingfromrheumatoidarthritisorosteoart...onalanti-inflammatory/analgesicactivityforalimited...
(Date:11/23/2009)...n the November issue of GIE: Gastrointestinal End...nal of the American Society for Gastrointestinal E...y found that Barrett,s esophagus was detected in s...opic screening. Also in this issue, two studies ex...om France, in the largest single-center experience...
(Date:11/23/2009)...build-up of a brain peptide called amyloid-beta. T...us of almost all drug research pursuing a cure for...But that may be counterproductive, says Dr. Inna S...iology and Pharmacology, Sackler Faculty of Medici...beta is also necessary to maintain proper brain fu...
(Date:11/23/2009)...Call/--AnnTaylorStoresCorp.announcedtodaythatitwil...sandGivingcampaign,aholidayfundraisingandawareness...armarksthethirdyearthatAnnTaylor,throughitsANNCARE...mpaignwhereweofferourshoppersanopportunitytohelpsa...hisholidayseason.ClientswhoshopatAnnTaylor,Loft,An...
(Date:11/23/2009)...ed longer-term support than most friends, relative...ing to a study of 160 patients published in the De...Nursing . , Researchers surveyed 55 patients...her with 105 who had had surgery in the last one t...in Tennessee, USA. They wanted to see if there was...
Breaking Medicine News(10 mins):Health News:Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card 2Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 2Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 3Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 4Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 5Health News:Upending textbook science on Alzheimer's disease 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 2Health News:Drug side effects a key factor in reduced quality of life for kidney transplant patients 3
...ntists from University of California have develope...cells which could help in the treatment of spinal ...ing results in the stimulation of nerve cells in l...oung and doesnot grow when it has become old, the ...
...essor Karen Gripp and his team from DuPont Hospita...ad to Costello Syndrome, scientists found that the...it was not observed in the genotype of the parents...don 12 or 13 in the H-ras gene in 85% patients. Th...
...Lancet has published a new study which challenges ...od to the heart. The study asserts that the harm i...benefits. Conventional medical wisdom states that ...ealand cite a large US study published earlier thi...
...search team of scientists at the Columbia Universi...eight when compared to keeping it off. // The key ...ppetite. The hormone helped people to avoid puttin...he metabolic thermostat of the body is reset upwar...
...galese schoolchildren took a pledge to abstain fro...DS Day. The prevailing taboos in the developing na...ntributing towards the disease spreading rapidly. ...courge is continuing to take a heavy toll in the A...
...ish researchers have expressed hope regarding the ...virus. The first phase of the clinical trials have...volunteers. DNA vaccines represent the lates... vaccines precipitate an immune response so that t...
Other Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2
(Date:11/23/2009)...ire-FirstCall/--RaptorPharmaceuticalCorp.("Raptor"...sentationofclinicaltrialdataonNGX426,theCompany,so...ntagonist,atthe12thInternationalConferenceontheMec...r20-21inSanFrancisco.TheresultsofthestudyledbyMark...eCenterforPainMedicineoftheUniversityofCaliforniaa...
(Date:11/23/2009)...ewswire-FirstCall/--NeurobiologicalTechnologies,In...ofdirectorshasdeclaredanextraordinarydividendof$0....,2009tostockholdersofrecordasofNovember30,2009.The...derapprovalofthedissolutionofNTIpursuanttoaplanofc...rdinarydividendof$0.75persharethatwaspaidtoshareho...
(Date:11/20/2009)...swire/ -- The United States Court of Appeals for ... ruling yesterday, approving a settlement in the l...utical litigation against AstraZeneca Pharmaceutic...gi-bin/prnh/20080317/AQM144LOGO ) ,, The ruling...urchased the pharmaceutical giant,s prostate cance...
Breaking Medicine Technology:Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 3Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 4Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 5Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3HEALTHeCAREERS Network Renews 2415 000 Scholarship Pledge 59787 1HEALTHeCAREERS Network Renews 2415 000 Scholarship Pledge 59787 2HEALTHeCAREERS Network Renews 2415 000 Scholarship Pledge 59787 3Psychiatric disorders and sexual trauma are associated with lower urinary tract symptoms 59785 1Psychiatric disorders and sexual trauma are associated with lower urinary tract symptoms 59785 2Judge Halts IHSS Home Care Cuts 3B Says They Likely Violate Federal Law 59781 1Judge Halts IHSS Home Care Cuts 3B Says They Likely Violate Federal Law 59781 2
...Mo.--(BUSINESS WIRE)--May 4, 2007 - New data have,...erosis (RRMS),patients treated with COPAXONE(R) (g...osuppression with mitoxantrone experienced a,90 pe...)-monitored,disease activity compared to their bas...ere sustained throughout the 24-month study,period...
...ngland, 4th May 2007 - CeNeS Pharmaceuticals plc,(...ompany, notes,the publication of an independent st... on its Phase II NMDA antagonist, CNS 5161. CeNeS,...r neuropathic,pain. The independent study builds o...CNS 5161. , In the study reported in ,Synapse, Dr...
Other Medicine Technology:Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
Vitreoretinal Viscodissector 90 degrees
Infusion Cannula 6mm
DCR Set
IOL Manipulator - Sinskey
Medicine Products: